Physician profile
Raied Abdullah
NPI 1063417657
$4,288.96
in general payments reported to CMS, 2019-2025
26 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $292 · 2021: $243 · 2022: $631 · 2023: $613 · 2024: $880 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158 · Education: $30.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.37 |
| Education | $30.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $699.00 | 2019-2025 | Farxiga |
| Amgen INC. | $575.34 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Vifor Pharma, INC. | $402.19 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $360.56 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $290.38 | 2019-2025 | Thiola |
| Opko Pharmaceuticals, LLC | $270.98 | 2019-2024 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $268.03 | 2019-2024 | |
| Ardelyx, INC. | $215.24 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Fresenius USA Marketing, INC. | $209.28 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $200.54 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $192.65 | 2022-2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $102.78 | 2025 | |
| Ekos Corporation | $93.33 | 2019 | |
| Merck Sharp & Dohme LLC | $88.80 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $65.00 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $62.42 | 2023 | Krystexxa |
| Novo Nordisk INC | $51.34 | 2024-2025 | Ozempic |
| Glaxosmithkline, LLC. | $46.19 | 2021-2023 | Benlysta |
| Mallinckrodt Enterprises LLC | $24.13 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.06 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.97 | 2025 | |
| Baxter Healthcare | $15.26 | 2022 | |
| Daiichi Sankyo INC. | $14.49 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raied Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.